Akili Company Overview
Akili
About Akili
Akili (NASDAQ:AKLI) focuses on developing digital therapeutics to treat cognitive impairments. The company's innovative approach combines scientific research with digital technology to create immersive, therapeutic video games designed to help manage disorders such as ADHD, depression, and autism among others. Akili actively works on expanding its portfolio of treatments, aiming to reach a broader patient population. Its flagship project, a game-based treatment for children with ADHD, showcases the company's commitment to reimagining medicine. By leveraging cutting-edge technology and rigorous scientific methods, Akili strives to improve mental health and cognitive function, making a significant impact on patients' lives around the globe.
What is Akili known for?
Snapshot
2011
Year founded
162
Employees
Boston, United States
Head office
Loading Map...
Operations
All Locations
Boston, US
Products and/or services of Akili
- EndeavorRx, the first FDA-cleared prescription treatment delivered through a video game for children with ADHD.
- AKL-T01, a therapeutic digital treatment designed to improve attention in children with ADHD.
- AKL-T02, aimed at treating cognitive impairments in adults with depression.
- AKL-T03, an investigational treatment for cognitive dysfunction in patients with multiple sclerosis.
- Digital Biomarkers, innovative tools for assessing cognitive and neural health in clinical trials and care.
Akili executive team
- Dr. Walter Edward Martucci II, Ph.D.Co-Founder & Chairman
- Mr. Matthew Franklin M.B.A.President, CEO & Director
- Dr. Adam Gazzaley M.D., Ph.D.Co-Founder, Chief Science Advisor & Director
- Ms. Jacqueline L. Studer J.D.Chief Legal Officer, General Counsel & Secretary
- Ms. Caty ReidVP of Marketing & Communications
- Dr. Scott H. Kollins Ph.D.Chief Medical Officer
- Mr. Jonathan DavidChief Product Officer